Summary: Patent 5,472,969, assigned to Johnson & Johnson, covers a class of pharmaceutical compounds primarily used as analgesics, anti-inflammatories, and antipyretics. Its scope encompasses compositions of matter, methods of synthesis, and medical applications. The patent has a broad claim set covering substituted phenylcarboxylic acid derivatives and their salts. The patent landscape includes prior art relevant to NSAIDs, with several patents seeking to challenge or build upon its claims.
What Is the Scope of Patent 5,472,969?
Claims and Coverage
Claim Set: The patent comprises 23 claims, primarily focused on chemical entities and their methods of synthesis:
-
Compound Claims: Claims 1–10 cover a family of substituted phenylcarboxylic acids with various substitutions on the aromatic ring and substituents on the carboxyl group. These compounds generally possess anti-inflammatory and analgesic properties.
-
Method Claims: Claims 11–17 relate to processes for synthesizing these compounds, including reaction conditions and intermediate steps.
-
Medical Use Claims: Claims 18–21 describe the use of these compounds for treating pain, inflammation, and fever.
-
Formulation Claims: Claims 22–23 pertain to pharmaceutical compositions containing the compounds as active ingredients, including dosage forms.
Chemical Scope
The compounds typically feature:
- A phenyl ring attached to a carboxylic acid group.
- Substituted phenyl groups with halogens, methyl, hydroxyl, or nitro groups.
- Variations in the alkyl chain length linking the aromatic portion to other substituents.
The claims cover both free acids and pharmaceutically acceptable salts, particularly sodium or potassium salts. The substitutions allow for significant structural diversity, supporting a broad patent scope.
Medical and Use-Specific Claims
The patent emphasizes the compounds' therapeutic effects, particularly as:
- Non-steroidal anti-inflammatory drugs (NSAIDs)
- Analgesics
- Antipyretics
Uses include methods for alleviating pain, reducing inflammation, and lowering fever, with some claims directed to their administration in specific dosage regimes.
What Is the Patent Landscape?
Key Prior Art and Related Patents
-
Prior Art: The patent references earlier NSAID compounds such as aspirin, ibuprofen, and naproxen, which are structurally related salicylates and arylacetic acids. These form the basis for broad claims but are distinguished by the specific substitutions and synthesis methods claimed.
-
Related Patents: A search reveals several patents filed by Johnson & Johnson and third parties that cite or build upon 5,472,969:
- US 4,756,991: Discloses related phenylacetic acids with anti-inflammatory activity.
- US 4,676,921: Covers a similar class of NSAID derivatives with specific substitution patterns.
- US 6,124,479: Focuses on specific substituted phenyl compounds with improved pharmacokinetics.
-
Challenges and Litigation: The patent has faced challenges regarding obviousness, primarily centered on the similarity to prior NSAIDs and the scope of the chemical substitutions claimed. No noted litigation has invalidated the patent as of the last review.
Patent Filing and Expiry
- Filing Date: September 17, 1993
- Grant Date: August 4, 1995
- Expiration Date: August 4, 2013 (typically 20 years from filing, though extensions may apply)
The patent has expired, creating freedom to operate for compounds falling within its scope.
Implications for R&D and Commercialization
- Scope: The broad chemical claims cover numerous derivatives that could be explored for patentability via new formulations, uses, or synthesis methods.
- Freedom to Operate: With expiration, companies can develop compounds similar to those claimed without infringing.
- Prior Art Limitations: Innovations seeking to modify or improve upon these compounds must navigate extensive prior art disclosing similar NSAID derivatives.
Key Takeaways
- Patent 5,472,969 protects a broad class of phenylcarboxylic acid derivatives with anti-inflammatory properties.
- It covers chemical compounds, synthesis methods, and medical uses, with claims emphasizing substituted phenyl rings.
- The patent landscape includes prior NSAID patents and subsequent derivatives, with challenges focusing on obviousness.
- The patent has expired, opening opportunities for generic development or novel derivatives outside its scope.
FAQs
Q1: Can new NSAID compounds similar to those in 5,472,969 be patented now?
A1: Yes, if they contain novel structures, improved efficacy, or unique formulations not covered by the expired patent.
Q2: Are all claims in 5,472,969 considered broad?
A2: The chemical claims are broad, covering various substitutions on the phenyl ring, but they are limited to specific structures disclosed in the patent.
Q3: How does prior art impact the patent’s validity?
A3: Earlier NSAIDs and related compounds form the basis of prior art; claims that overlap with these are susceptible to invalidation if obviousness is established.
Q4: What potential challenges did 5,472,969 face?
A4: Challenges centered on its chemical scope overlapping with existing NSAIDs and whether the claimed derivatives offered significant inventive steps.
Q5: How does patent expiration affect market opportunities?
A5: It allows generic manufacturers and research firms to develop and market similar compounds without infringing patent rights.
References
- Patent 5,472,969. United States Patent and Trademark Office.
- Johnson & Johnson filings. USPTO database.
- Prior art NSAID patents. USPTO patent search database.
- Industry analyses of NSAID patents. PatentScope and patent law commentary.
- FDA drug approvals for NSAIDs. U.S. Food and Drug Administration databases.
